The New Year edition looks forward with vim, vigour and vision! We are, after all, in the midst of transformation. In drugs, through development, across trials and amid the melting both of digital and AI. It is – at once – exciting, curious and slightly imposing. In this edition we focus on all the aforementioned themes, and NHS turbulence, predictions for 2026, healthcare comms, the future of GLP-1s, online pharmacies, radiology progress, patient centricity 2.0 and more.
The bells are ringing out for another spectacular Christmas edition of PharmaTimes. This year, we recline and reflect on a transformative year across the pharmaverse, with wistful reminiscences from our panel of industry gurus. There is also plenty to unwrap from the NHS, as we explore how pharma will be breaking bread with public health in the months ahead. The bountiful gifts include features on medical innovation, a BAFTA-nominated film on women’s health, partnering with patients, igniting modern comms and tackling the curious trend of ‘stacking’. We also bring reports from our latest, lavish award ceremonies. Deploy the party poppers!
In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and speculate about the possibilities built on the founding principles, but without any of the peeling paint and dated equipment. There are also features that focus on the conditions of our times – MND, mental health and even the very skin we live in. Yep, this feels like a pretty important issue, as further deep dives into clinical trials, the top ten drugs of 2025 and the importance of child patient safety so boldly testify. All the regulars complete a stunning line up!
As an occupation at the very epicentre of healthcare, the nurse is a constant and iconic presence. In this edition of PharmaTimes, we demonstrate how this reassuring and essential presence within our industry’s ecosystem continues to evolve. Talking of evolution, we will also fearlessly segway into the all-encompassing era of AI. Once a vague conversation, but now an often inspiring but slightly daunting reality, the robots are here to stay! In addition, we check out pharmacovigilance, dissect Keir Starmer, explore clinical trial data, peruse patient access and much, much more!
The new era of pharma is not just here – we are living through it. Our latest issue is about progress, getting there and arriving.
In this bold edition we talk about weight loss drugs – are they healthcare products, an NHS saviour or a complex cosmetic project? We also follow the astonishing and seemingly unstoppable acceleration of AI and the instant impact it is having on industry marketing, the use of data and humankind itself. Features on future innovation, decoding Parkinson’s disease, pharmacovigilance, the link between animal and public health, a review of our International Clinical Researcher of the Year Awards and what decisions must be made about the NHS, complete a tubthumping edition of pharma’s most intrepid periodical.
As new Pharmatimes, equidistant between the beginning and end of 2025, launches we can never be accused of ducking the Zeitgeist! Indeed, we seize weight loss drugs, NHS rebooting, AI impact, vaccine progress, clinical trials evolution and culture shaping with steely determination. It is, after all, the most transformative chapter in our industry’s history…
The spectre, the shadow, the shock to the system! Yes, folks, this time we are focussing on the accumulation of humanity’s biggest dreams and worst nightmares. It’s AI time! And we’re talking about AI healthcare, AI public health, AI hospitals, AI pharma and AI patients. It’s the force of neo-nature over which we have some but not all control, and the pages of this periodical do not dodge the issues dominating our industry.
As the cover so boldly suggests, we’re talking ‘women in pharma’. Progress, ambitions, direction, understanding and essence. Indeed, this edition focuses on the dimensions of difference that only women can offer – it is about shaping new cultures through equity, the transformational possibilities of women leading and igniting clinical trials through gender distinction. Above all, we are highlighting why the future for women across life sciences must equate to proportional representation. Meanwhile, we’ve also got features on antibiotics resistance, AI assisted health outcomes, the rebuilding of UK public health and how a pub is triggering conversations about men’s health.
This edition of PharmaTimes is about the radical new look that pharma rocks these days – with it emerging dimensions, possibilities and cultures. In the spirit of this realisation, we look at the increasing role of selfcare as part of reshaping national health, while also appreciating why the laser focus of modern meds must come with adherence.
The great table of debate has been pulled up, as argument and counter argument wrestle for supremacy in the first tubthumping PharmaTimes of the year. Indeed, we stare down all the most pressing issues of 2025 including AI, modern comms, misinformation, mass screening, weight loss drugs, the future of the NHS, digital drugs and the promised land of patient inclusivity. Yep, this year – more than any other in human history
The Christmas edition arrives but once a year and, as the cover boldly suggests, this is the Christmas edition! Within the pages of our frost encrusted periodical, we will find 12 industry luminaries issuing wistful recollections of the year just passed, while embarking on a dalliance with the future. And, mark my words, if the prophecies of these prophetic prophets turn out to be true, 2025 will be a year like no other.
Isn’t it great to be at the forefront of a radically changing industry! Just in case the robots are reading, PharmaTimes has been onboard with AI from the get go – and this edition is no exception. Indeed, we look at how AI can be a force for good across the pharmaverse – from optimising R&D to advanced analytics.
This month’s PharmaTimes has all three eyes on an unknown but radical future. As with all new, unwritten health-based chapters, it will unfold in a way that is largely shaped by the human race. Except this time, we will be duty bound to shape the unreal – to mould the artificial! No pressure, then.
And, so, here we are – Keir we are, if you will. A brave new era nationally translates to an interesting adventure for both pharma and wider healthcare. This month we go big on the reality of political, infrastructural and institutional change. This edition also focuses on the all-encompassing, ever-evolving spectre of AI – what it is, what it wants and how it can be shaped meticulously into a force for good.
